Loading…
AVITA Medical, Inc. is projected to rise to $4.75 by 2027, a +8% move from its current price of $4.40. RCEL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $4.23 | $4.40 | $4.58 | -0.03% |
| Aug 5 | $4.16 | $4.40 | $4.65 | -0.06% |
| Aug 6 | $4.10 | $4.40 | $4.71 | -0.10% |
| Aug 7 | $4.06 | $4.39 | $4.76 | -0.13% |
| Aug 8 | $4.02 | $4.39 | $4.80 | -0.16% |
| Aug 9 | $3.98 | $4.39 | $4.84 | -0.19% |
| Aug 10 | $3.95 | $4.39 | $4.88 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.95 | $4.39 | $4.88 | -0.22% |
| Week 2 | $3.77 | $4.38 | $5.08 | -0.45% |
| Week 3 | $3.64 | $4.37 | $5.24 | -0.67% |
| Week 4 | $3.53 | $4.36 | $5.38 | -0.89% |
| Week 5 | $3.44 | $4.35 | $5.50 | -1.12% |
| Week 6 | $3.36 | $4.34 | $5.62 | -1.34% |
| Week 7 | $3.28 | $4.33 | $5.72 | -1.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
AVITA Medical sells and distributes PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical is headquartered in Valencia, California.
RCEL is trading at $4.61 with a market cap of $141.88M and is ranked 3942. The stock sits near its 50-day simple moving average of $4.35 and its 200-day simple moving average of $4.19. The 30-day price range runs from $3.41 to $6.24, with a near-term support level at $3.91 and a resistance level at $5.19.
The forecast suggests a path of upside over the coming years, with 2026 avg $4.61 and rising toward 2030 and beyond. By 2030, the avg is $6.14 with a max of $10.15 and a min of $4.02, and by 2050 the avg is $31.59 with a max of $72.66. The longer-horizon outlook is BULLISH, reflecting a substantial potential appreciation, though these are estimates and not guarantees.
A major floor 26.5% below — a decisive break under it would weaken the trend.
The nearest floor, 10.9% below — buyers have tended to step in here.
The nearest ceiling, 18.0% above — a clean break opens room to run.
A major ceiling 31.2% above — clearing it would confirm fresh momentum.
Key RCEL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCEL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.54 | Sell | $4.52 | Sell |
| MA 10 | $4.71 | Sell | $4.59 | Sell |
| MA 20 | $4.66 | Sell | $4.58 | Sell |
| MA 50 | $4.38 | Buy | $4.47 | Sell |
| MA 100 | $4.37 | Buy | $4.41 | Sell |
| MA 200 | $4.17 | Buy | $4.66 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.41 | Neutral |
| Stoch RSI (14) | 13.46 | Buy |
| CCI (20) | -57.57 | Neutral |
| Williams %R (14) | -66.07 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -6.98 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 33.93 | Neutral |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 0.10 | Buy |
| Ultimate (7,14,28) | 36.52 | Neutral |
| Momentum (10) | -0.70 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 4.39 | Buy |
| ADX (14) | 12.69 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day technical picture shows a bullish tilt, supported by a neutral RSI(14) of 50. The stock trades near the 50-day SMA of $4.35 and above the 200-day SMA of $4.19, indicating a constructive intermediate trend. The 30-day range spans $3.41 to $6.24, with a near-term support at $3.91 and resistance at $5.19.
Annualized volatility is elevated at 90%, underscoring a wide trading range in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.28 | $4.40 | $5.78 | 0% | Neutral | |
| $3.64 | $4.75 | $6.66 | +8% | Neutral | |
| $3.76 | $5.14 | $7.58 | +17% | Neutral | |
| $3.64 | $5.15 | $7.90 | +17% | Neutral | |
| $4.25 | $6.21 | $9.85 | +41% | Bullish | |
| $5.25 | $7.91 | $12.90 | +80% | Bullish | |
| $5.81 | $9.00 | $15.06 | +105% | Bullish | |
| $5.71 | $9.09 | $15.56 | +107% | Bullish | |
| $5.11 | $8.33 | $14.56 | +89% | Bullish | |
| $5.64 | $9.43 | $16.79 | +114% | Bullish | |
| $7.65 | $14.33 | $27.65 | +226% | Bullish | |
| $14.54 | $32.31 | $69.83 | +634% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.28 | $4.40 | $5.54 | +0.00% |
| September 2026 | $3.73 | $4.47 | $5.55 | +1.63% |
| October 2026 | $3.53 | $4.27 | $5.39 | -4.44% |
| November 2026 | $3.56 | $4.35 | $5.55 | +1.72% |
| December 2026 | $3.65 | $4.48 | $5.78 | +3.16% |
Click any year to see its month-by-month RCEL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RCEL could reach as high as $5.78, with a base case around $4.40 and support toward $3.28 — roughly 0% from $4.40. A consolidation phase looks the most probable path here.
Expect RCEL to range from $3.64 to $6.66 through 2027. The $4.75 average target implies a +8% move from current prices. That is up +8% on the projected 2026 average. Price action looks broadly range-bound.
The RCEL price prediction for 2028 points to an average of $5.14 (low $3.76, high $7.58) — a potential gain of +17% on today's $4.40. A consolidation phase looks the most probable path here.
In 2029, RCEL is projected to trade between $3.64 and $7.90, averaging $5.15 — a potential gain of +17% from today's $4.40. That is up 0% on the projected 2028 average. Price action looks broadly range-bound.
AVITA Medical, Inc.'s 2030 outlook centres on $6.21, within a $4.25 to $9.85 range. That is up +21% on the projected 2029 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, RCEL could reach as high as $12.90, with a base case around $7.91 and support toward $5.25 — roughly +80% from $4.40. Momentum favours further upside here.
Expect RCEL to range from $5.81 to $15.06 through 2032. The $9.00 average target implies a +105% move from current prices. That is up +14% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The RCEL price prediction for 2033 points to an average of $9.09 (low $5.71, high $15.56) — a potential gain of +107% on today's $4.40. Momentum favours further upside here.
In 2034, RCEL is projected to trade between $5.11 and $14.56, averaging $8.33 — a potential gain of +89% from today's $4.40. That is -8% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
AVITA Medical, Inc.'s 2035 outlook centres on $9.43, within a $5.64 to $16.79 range. That is up +13% on the projected 2034 average. That marks a +114% change versus current levels. Momentum favours further upside here.
By 2040, RCEL could reach as high as $27.65, with a base case around $14.33 and support toward $7.65 — roughly +226% from $4.40. Buyers look set to stay in control over this stretch.
Expect RCEL to range from $14.54 to $69.83 through 2050. The $32.31 average target implies a +634% move from current prices. That is up +125% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RCEL today (≈ 227.272727 RCEL) could be worth
$7,343.43
+$6,343.43 (+634%) by 2050 · US Dollar
Based on the average projected RCEL price of $32.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCELwould be worth at today's price.
$1,000 invested in RCEL on Jul 31, 2025 (≈ 188.679238 RCEL) would be worth
$830.19
-$169.81 (-17.0%) today · 0.83× · US Dollar
Based on a RCEL entry price of $5.3 vs. today's $4.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.61 | $954.45 | -4.6% |
| 1 month ago | $4.67 | $942.18 | -5.8% |
| 3 months ago | $4.44 | $990.99 | -0.9% |
| 6 months ago | $4.24 | $1,037.74 | +3.8% |
| 1 year ago | $5.3 | $830.19 | -17.0% |
| All time (5.0y) ago | $18.82 | $233.79 | -76.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCEL forecast.
Our base-case forecast reaches $8.80 around 2032.
Implied market cap at $8.80: $270.83M
The multi-year forecast paints a progressive upside, with a neutral stance in 2026 (avg $4.61; min $3.28; max $6.12; ROI 0; sentiment NEUTRAL) transitioning to bullish in the 2030s and beyond. In 2030, the avg price is $6.14 with a max of $10.15 and a min of $4.02, yielding a 33.2% ROI and a BULLISH sentiment. The outlook remains strongly bullish into 2040, with an avg of $14.15, a max of $28.99, and a 207% ROI.
By 2050, the forecast shows an avg of $31.59, a max of $72.66, and a 585.3% ROI, with sentiment remaining BULLISH. These figures imply meaningful upside potential over the longer horizon, tempered by the usual market uncertainties and the caution that forecasts are not guarantees.
Tap a question to reveal the answer.
2030 avg $6.14; max $10.15; min $4.02; ROI 33.2%; sentiment BULLISH.
Longer-horizon forecasts are bullish, with 2030 avg $6.14 (ROI 33.2%) and 2050 avg $31.59 (ROI 585.3%), though 2026-2029 are NEUTRAL and these are estimates, not guarantees.
Yes. The 2030 max is $10.15.
Current price $4.61; market cap $141.88M.
30-day range low $3.41, high $6.24.
AVITA Medical, Inc. Community Discussion
0Share your AVITA Medical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.